article_metadata: Sasan Fazeli Edina Paal Jessica H Maxwell Kenneth D Burman Eric S Nylen Shikha G Khosla
article_metadata: 10.1177/2324709619890942
article_metadata: J Investig Med High Impact Case Rep
article_metadata: 2019 Jan-Dec;7:2324709619890942.
article_metadata: braf v600e braf inhibitor cdk4 mutation ezh2 mutation anaplastic thyroid cancer mitogen-activated extracellular protein kinase inhibitor (mek inhibitor) targeted therapy
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/31766881/
article_metadata: CDC2 Protein Kinase / genetics Enhancer of Zeste Homolog 2 Protein / genetics Molecular Targeted Therapy Proto-Oncogene Proteins B-raf / genetics Thyroid Carcinoma, Anaplastic / genetics Thyroid Neoplasms / genetics
article_metadata: CDC2 Protein Kinase / genetics Enhancer of Zeste Homolog 2 Protein / genetics Molecular Targeted Therapy Proto-Oncogene Proteins B-raf / genetics Thyroid Carcinoma, Anaplastic / genetics Thyroid Neoplasms / genetics Case Reports Aged Autopsy CDC2 Protein Kinase / antagonists & inhibitors Enhancer of Zeste Homolog 2 Protein / antagonists & inhibitors Fatal Outcome Humans Imidazoles Male Mutation Oximes Positron Emission Tomography Computed Tomography Protein Kinase Inhibitors / therapeutic use Proto-Oncogene Proteins B-raf / antagonists & inhibitors Pyridones Pyrimidinones Thyroid Carcinoma, Anaplastic / drug therapy Thyroid Neoplasms / drug therapy Imidazoles Oximes Protein Kinase Inhibitors Pyridones Pyrimidinones trametinib EZH2 protein, human Enhancer of Zeste Homolog 2 Protein BRAF protein, human Proto-Oncogene Proteins B-raf CDC2 Protein Kinase CDK1 protein, human dabrafenib
article_metadata: PMC6880026
article_metadata: 31766881
article_metadata: Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer
article_metadata: 2019